NICE - Endorsed Technology Appraisals 2009/2010

Technology Appraisals

Fully Endorsed

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA151 - Diabetes - Insulin Pump Therapy - HSC (SQSD) (NICE) 29/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA152 - Coronary Artery Disease - Drug Eluting Stents - HSC (SQSD) (NICE) 30/2009 - ‘Note this guidance has been partially updated by NICE Clinical Guideline NG185 - Acute coronary syndromes, which was endorsed by the DoH in September 2021’

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA153 - Entecavir for the Treatment of Chronic Hepatitis B - HSC (SQSD) (NICE) 39/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA154 - Telbivudine for the Treatment of Chronic Hepatitis B - HSC (SQSD) (NICE) 40/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA157 - Venous Thromboembolism - Dabigatran - HSC (SQSD) (NICE) 31/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA158 - Amantadine, Oseltamivir and Zanamivir for Influenza Prophylaxis - HSC (SQSD) (NICE) 41/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA160 - Osteoporosis - Primary Prevention - HSC (SQSD) (NICE) 32/2009

• This guidance has been partially updated by TA464 - Bisphosphonates for treating osteoporosis, which was endorsed by the DoH in September 2017.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA161 - Osteoporosis - Secondary Prevention Including Strontium Ranelate - HSC (SQSD) (NICE) 33/2009

• This guidance has been partially updated by TA464 - Bisphosphonates for treating osteoporosis, which was endorsed by the DoH in September 2017.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA163 - Infliximab for Acute Exacerbations of Ulcerative Colitis - HSC (SQSD) (NICE) 42/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA164 - Febuxostat for the Treatment of Hyperuricaemia in People with Gout - HSC (SQSD) (NICE) 46/2009

‘Note this guidance has been updated and replaced by NG219 - Gout: diagnosis and management, which was endorsed by the DoH in August 2022’

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA165 - Machine Perfusion Systems and Cold Static Storage of Kidneys from Deceased Donors - HSC (SQSD) (NICE) 43/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA167 - Endovascular Stent Grafts for the Treatment of Abdominal Aortic Aneurysms - HSC (SQSD) (NICE) 47/2009 - Note this guidance has been updated and replaced by NICE Clinical Guideline NG156 - Abdominal aortic aneurysm: diagnosis and management, which was endorsed by the DoH in August 2021

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA168 - Amantadine, Oseltamivir and Zanamivir for the Treatment of Influenza (review of TA58) - HSC (SQSD) (NICE) 44/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA170 - Rivaroxaban for the Prevention of Venous Thromboembolism after Total Hip or Total Knee Replacement in Adults - HSC (SQSD) (NICE) 48/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA172 - Head and Neck Cancer (squamous cell carcinoma) - Cetuximab - HSC (SQSD) (NICE) 65/2009

• This guidance has been updated and replaced by TA473 - Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck, which was endorsed by the DoH in September 2017.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA173 - Hepatitis B - Tenofovir Disoproxil Fumarate - HSC (SQSD) (NICE) 66/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA174 - Leukaemia (chronic lymphocytic) Rituximab - HSC (SQSD) (NICE) 67/2009